PipelineReview.com1h
Blenrep shows overall survival benefit in head-to-head DREAMM-7 phase III trial for relapsed/refractory multiple myeloma
LONDON, UK I 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 ...
The Fresh Market names Shipt its new delivery service
The Fresh Market’s most recent store opening in the Chicago neighborhood of Lincoln Park took the place of a Dom’s Kitchen ...
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why
On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...
STAT19h
Pharmalittle: We’re reading about a Merck deal, GSK cancer drug data, and more
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
FiercePharma21h
GSK's ADC Blenrep delivers survival win against J&J's Darzalex
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...
BioSpace21h
GSK Builds Case for Blenrep with Multiple Myeloma OS Data That Bests J&J’s Darzalex
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
GSK hails progress for withdrawn blood cancer drug
UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...
ENDPOINTS NEWS23h
GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta
GSK reported positive survival data for Blenrep combined with bortezomib and dexamethasone in multiple myeloma DREAMM-7 trial, outperforming daratumumab combination therapy. GSK plans US relaunch in ...